CONTENTS
Editorials
Acute ischemia and chronic ischemia. Mr. CAZAUBON............................... 5
SFA Report 2009. M. CAZAUBON et F.A. ALLAERT ............................................7
Arteries
Supportive Treatment with CoenzymeQ10 in Heart Failure: the Irvine3 labs in Heart Failure Study on Vascular
Patients. G. BELCARO, M. R. CESARONE, A. LEDDA, U. CORNELLI, M. DUGALL, S. STUARD,
E. IPPOLITO, M. G. GROSSI, I. RUFFINI .................................................... 9
Resistance to antiplatelet drugs: interest in clinical practice and laboratory tests for primary screening. S. ARMERO, F. PAGANELLI, l. CAMOIN-JAU, l. BONELLO .........................17
Lipid profile and cardiovascular risk of type 2 diabetes in Senegal.A. MBAYE, N.V. YAMEOGO,
Ad. KANE, A. DIACK, M.B. NDIAYE, B. DIACK, S. PESSINABA, A. THIAM, M. DIOUM, R. HAKIM, D. DIAGNE, M. KANE, M. NDOUR, M. DIAO, A. DIALLO, S.N. DIOP, A. KANE............................ 26
Venous arterialization of the foot as against the current treatment of critical limb ischemia. F. LENGUA,
A. LA MADRID, J. VARGAS, C. ACOSTA ................................ 31
Transcranial Doppler and sickle cell disease. S. VERlHAC, S. BAlANDRA ................................ 37
Venous thrombo embolic
Echo-Doppler monitoring after DVT: when, for whom?. F. CHLEIR .................................. 41
Veins
Should we take into account the genetic characteristics of venous ulcers? M. R. BOISSEAU, M. CAZAUBON............... 43
Neovascularization post-surgery is a fatality? What is the responsibility of the surgeon?. D. CRETON .................... 47
Proceedings of Congress
XLI Meeting of the European Society of Phlebectomy. Bellagio (Italy) - October 10, 2009. P.l. CHOUKROUN ...............................................56
Membership form to the SFA .......................................16
Announcement of Conference and events ......................................60
The new site ........................................62
Index authors and articles 2009............................................ 63
Advertisers list ...............................................71
Subscriptions ..............................................72
Instructions to Authors ............................................... Cover. 3